* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Xeris Biopharma Holdings's Total Payout Ratio
For the Biotechnology subindustry, Xeris Biopharma Holdings's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xeris Biopharma Holdings's Total Payout Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xeris Biopharma Holdings's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Xeris Biopharma Holdings's Total Payout Ratio falls into.
Xeris Biopharma Holdings Total Payout Ratio Calculation
Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.
Xeris Biopharma Holdings's Total Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xeris Biopharma Holdings Total Payout Ratio Related Terms
Thank you for viewing the detailed overview of Xeris Biopharma Holdings's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XERS has been successfully added to your 